You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

July 27, 2015

Protecting Unregistered IP with Unfair Competition Laws in Vietnam

Managing Intellectual Property

In early 2015, a European pharmaceutical company that markets a globally well-known pain relief drug discovered a drug with the same active ingredient and a similar name circulating on the Vietnamese market. In what the European company believed was a clear instance of “palming off,” the drug’s packaging also used colors and design elements similar to the packaging of the well-known drug. However, pursuing a trademark infringement charge was a dead end, as the Vietnamese drug’s name had already been successfully registered as a trademark.

Additionally, though it is possible to register trade indications (such as packaging designs or labels) as trademarks or industrial designs in Vietnam, affording the holder strong protection, the European company had not done so. Instead, the company resorted to Vietnam’s unfair competition laws to protect its trade indications.

Unfair Competition in Vietnam

In Vietnam, the concept of unfair competition in the IP field conforms largely to the regulations under Article 10 bis of the Paris Convention. Provisions on unfair competition in IP are found in both the Competition Law and the IP Law, though only the Competition Law provides a definition, which refers to acts that run contrary to good conscience in business practice. The Competition Law also mentions some typical acts of unfair competition, including the use of misleading trade indications, but shifts the responsibility for providing further details to the IP Law of 2005, which prohibits any use of trade indications with the purpose of causing economic injury to another business through confusion in the course of trade.

Under the unfair competition laws, a holder of unregistered trade indications can enforce its rights through civil litigation before the court, administrative action conducted by administrative enforcement bodies, or competition proceedings carried out by the Vietnam Competition Authority under the Ministry of Industry and Trade. While this may appear to be a wide range of available legal actions, in practice, most holders rely on the administrative enforcement bodies (usually the Ministry of Science and Technology (MOST) Inspectorate).

Proving Unfair Competition

To successfully argue unfair competition, a holder must conclusively prove that:

  1. it is the legitimate owner of the unregistered subject matter (packaging, labels, slogans, etc.);
  2. the subject matter has become a trade indication of the holder; and
  3. he use of the subject matter by third parties could confuse the buying public as to the origins of the products in question.

In practice, to prove the two first conditions, the competent authorities often require the IPR holder to establish the wide use of the subject matter prior to the market entry of the offender’s products in Vietnam.

Due to the lack of IP registration, the enforcement bodies are often reluctant to resolve cases independently. In most cases, they seek an expert opinion from the National Office of Intellectual Property (NOIP) on the possibility of unfair competition arising from the use of the trade indications in question. Therefore, an expert opinion, though nonbinding, usually tips the balance in unfair competition cases.

In the pain-relief-drug case cited above, the rights holder selected the MOST Inspectorate, an agency with significant experience in similar cases, as the enforcement body. The company was then able to successfully establish and provide evidence that its packaging was widely used and well-known, leading the Inspectorate to render a final ruling in favor of the holder without first asking for the NOIP’s opinion. This marks a significant improvement in the authority’s determination to resolve unfair competition cases. The case was also remarkable as it lasted just over three months, which is quite expedient for unfair competition cases in Vietnam. At the conclusion of the case, more than 100,000 infringing goods and 400 kg of aluminum foil imprinted with the infringing trade dress were ordered to be destroyed—a major victory for the European company. If this case had been handled by a different agency, the results could have been much different.

Recommendations

We have drawn from our practice the following recommendations for IPR holders to ensure success in cases of unfair competition related to the use of misleading trade indications:

  • Register the trade indication, if applicable, as soon as possible. The holder can register the entire packaging of its products as a trademark and/or industrial design (in some cases). With the registrations, the holder will stand a higher chance of successfully protecting the packaging.
  • Try to establish the goodwill of the unregistered trade indication with documentation evidencing the goodwill, such as advertising materials, goods-related sales, or charity activities.
  • Choose an agency with expertise and experience, such as the MOST Inspectorate, to handle the case. The court should be a last resort, only when there is a claim for damages.

RELATED INSIGHTS​ 

July 25, 2025
Over the first half of 2025, the government of Vietnam has implemented a comprehensive suite of legislative reforms that significantly impact the country’s intellectual property (IP) framework. These amendments, most of which took effect on 1 July 2025, span the criminal, civil, administrative, and judicial sectors, and are part of a broader initiative to modernize Vietnam’s legal infrastructure, strengthen enforcement mechanisms, and harmonize domestic regulations with international standards. A summary of the key legislative changes and their potential implications for IP protection and enforcement across Vietnam is provided below. Criminal Code: Stricter penalties Under the 2025 amendments to Vietnam’s Criminal Code, penalties for offenses involving the manufacturing and trading of counterfeit goods have been significantly escalated. Individuals convicted of such violations now face fines ranging from VND 200 million to VND 2 billion (approximately USD 7,700 to USD 77,000; up from VND 100 million to VND 1 billion). For corporate entities, the penalties are even more severe, with fines ranging from VND 2 billion to VND 40 billion (roughly USD 77,000 to USD 1.54 million; up from VND 1 billion to VND 20 billion). These heightened penalties reflect the government’s intensified efforts to deter counterfeit-related crimes and protect consumer rights. Law on Handling Administrative Violations: Extended statute of limitations and application of electronic procedure The statute of limitations for addressing administrative violations in the IP sector is still two years. However, in cases where such violations are referred by procedural authorities, this period is extended by one year. The time taken by these authorities to process the case is now included within the overall limitation period. In addition, the Law on Handling Administrative Violations facilitates the use of electronic procedures, provided that the necessary infrastructure, technical systems, and information conditions are in place. Specifically, enforcement authorities are now permitted
July 21, 2025
Distinctiveness is a fundamental requirement for a trademark’s registration and protection under Thai law. The Thai courts typically assess distinctiveness based on a mark’s inherent characteristics rather than its use, as proving acquired distinctiveness through use requires substantial evidence, including the duration of use, extent of distribution and promotional efforts. However, the Intellectual Property and International Trade Court (IP & IT Court) has recently ruled that the figurative mark WEPLAY had acquired distinctiveness through use – an uncommon ruling under Thai trademark law. Subsequently, the Court of Appeal for Specialised Cases affirmed the mark’s inherent distinctiveness based on a holistic assessment of its components. This article discusses the criteria for proving both inherent and acquired distinctiveness, offering examples from both courts to provide valuable insights into case preparation and understanding of how the courts assess distinctiveness. Background In 2017 the plaintiff filed a trademark application for the mark depicted below for goods in Class 28, including toy building blocks: The registrar rejected the application on the grounds of non-distinctiveness under Section 7 of the Trademark Act. The plaintiff appealed to the Board of Trademarks, which considered that, when the term ‘weplay’ is used for goods in Class 28, it is descriptive of the nature of the goods applied for as “playthings”. Therefore, ‘weplay’ was deemed nondistinctive under Section 7, Paragraph 2(2) of the Trademark Act. IP & IT Court decision In 2024 the IP & IT Court ruled that the term ‘weplay’ is not a coined or invented word; instead, it is a combination of ‘we’ and ‘play’, conveying the meaning of ‘we play’. When the term is used for goods in Class 28, it describes the nature of the goods as “playthings”. Consequently, the mark was deemed non-distinctive. However, the court considered the evidence presented by the plaintiff,
July 14, 2025
Life sciences specialists from Tilleke & Gibbins have updated the firm’s guide to pharmaceutical data exclusivity regulations and practices in Southeast Asia. This guide contains quick-reference information on the availability of data exclusivity protections and limitations in Cambodia, Indonesia, Laos, Malaysia, Myanmar, Thailand, and Vietnam. Developing and launching a new drug on a commercial scale requires an enormous amount of time and investment in research and development (R&D), including pre-clinical testing and clinical trials. When considering the aggregate amount of drug development costs, it is important to recognize that this includes not only the investment in developing new drugs that get approved by a government food and drug regulator and are successfully brought to market, but also the R&D expenditures on a large number of potential pharmaceutical compounds and products that never actually make it to market. In particular, considerable investment is required in order to conduct and produce clinical trial data—to prove safety, efficacy and effectiveness of a new drug—that would warrant marketing approval by the regulatory authority. Such data is proprietary in nature and highly valuable for a research-based pharmaceutical company that develops an original drug. On the other hand, patent law typically confers generic drug manufacturers with the ability to engage in various preparatory activities with a view to obtaining marketing approval for a generic product before the patent for the original drug expires (commonly known as a “Bolar provision”). Since a generic drug maker may submit an application for marketing approval of a generic product before the relevant patent expires, the extent to which the drug originator’s data submitted to the regulatory authority is protected—or in other words, the extent to which the generic company may rely on the drug originator’s previously filed data, which underpins the safety and efficacy of the drug, to support
June 30, 2025
Vietnam is making notable strides in decentralization, aiming to grant greater autonomy to local government entities to streamline administrative procedures. As part of this effort, the government issued Decree No. 133/2025/ND-CP on decentralization of state management of the Ministry of Science and Technology dated June 12, 2025 (Decree 133). Effective from July 1, 2025, Decree 133 decentralizes and delegates numerous state management functions—including in intellectual property (IP) and technology transfer—to provincial-level People’s Committees (PCs). This reform signals a profound shift in how IP rights are administered and enforced across Vietnam. While this offers new opportunities for IP owners, agents, and innovators, it also introduces additional operational complexities. Impact on IP and Technology Transfer Decree 133 significantly reallocates responsibilities in IP and technology transfer, primarily to provincial-level PCs. Provincial PCs and other provincial authorities are now empowered to handle a wide range of tasks, including but not limited to the following: Issuance of duplicates and reissuance of certificates of registration. Registration of license agreements for the transfer of usage rights for industrial property objects (e.g., trademarks, patents) and recording amendments, extensions, or early terminations of such agreements. Enforcing decisions on compulsory licensing of patent use rights. Evaluation and approval of technology transfer contracts—a key step in facilitating localized technological advancements. Permitting the establishment of foreign-invested scientific organizations and their branches, to encourage foreign direct investment in local R&D and technology development. Approval of provincial-level R&D tasks, aligning with local socio-economic development priorities. Legal Implications The decentralization and delegation brought forth by Decree 133 carry several significant legal implications: Echoing Decree 133, the Intellectual Property Office of Vietnam issued Notification No. 2351/TB-SHTT on June 26, 2025, announcing the cessation of 19 administrative procedures at the national level. Specifically, from July 1, 2025, the IP Office will no longer accept requests related